Apr 17 2010
Hosted by Global Leaders Institute, "VacChina 2010", a Vaccine Development Summit to be held from September 15-16, 2010, will bring together the world's major vaccine players and their respective senior level representatives to Shanghai, the heart of China's biopharmaceutical innovation.
China's vaccine industry has been under a spotlight following the recent events of Novartis-Zhejiang Tianyuan deal and GSK-Yunan Walvax JV.
Dr. Daniel Vasella, Chairman and CEO of Novartis commented, "Novartis has a long-standing commitment to improving healthcare in China. Our future activities with Tianyuan are an important step in our strategy to enhance the prevention of diseases in China with high-quality products."
"The joint venture would help bring more of GSK's technologies to China," added GlaxoSmithKline CEO Andrew Witty. GSK also signed a deal with Yunnan Walvax Biotech in October to co-launch a company that focuses on pediatric vaccines, with an initial investment of 451 million yuan from the two companies.
Over 200 senior executives from international vaccine suppliers including GlaxoSmithKline, Sanofi Pasteur, Novartis, Merck, Pfizer, Crucell, MedImmune, Intercell, as well as domestic leaders including Sinopharm, Sinovac, Hualan Bioengineering, Zhejiang Tianyuan Biopharmaceuticals, Tiantan Bio, Yunan Walvax and Simcere will present at the event.
Following the recent vaccine safety incidents in Shanxi and Jiangsu, safety issues have been brought to the top of agenda for first time. A roundtable housing a panel of China's vaccine industry leaders and experts from the Chinese Center for Disease Control and Prevention will join the discussion on strategies employed in ensuring efficacious and safe vaccines.
"VacChina 2010" Vaccine Development Summit brings together thought leaders from the world's leading vaccine manufacturers, biotechs, service providers, governmental agencies, research and academic institutes.
Study shows potential for universal flu vaccine with broad antibody response